|
|
Volumn 1, Issue 3, 2003, Pages 116-122
|
|
Use of highly potent bisphosphonates in the treatment of osteoporosis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
BISPHOSPHONIC ACID DERIVATIVE;
DRUG DERIVATIVE;
ETIDRONIC ACID;
IBANDRONIC ACID;
RISEDRONIC ACID;
AGED;
BONE DENSITY;
BONE REMODELING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG EFFECT;
FEMALE;
HOSPITALIZATION;
HUMAN;
MALE;
METHODOLOGY;
MIDDLE AGED;
OSTEOPOROSIS;
PATHOLOGIC FRACTURE;
PHYSIOLOGY;
POSTMENOPAUSE OSTEOPOROSIS;
PROGNOSIS;
RADIODENSITOMETRY;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
TREATMENT OUTCOME;
AGED;
AGED, 80 AND OVER;
ALENDRONATE;
BONE DENSITY;
BONE REMODELING;
DENSITOMETRY, X-RAY;
DIPHOSPHONATES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
ETIDRONIC ACID;
FEMALE;
FRACTURES, SPONTANEOUS;
HUMANS;
MALE;
MIDDLE AGED;
OSTEOPOROSIS;
OSTEOPOROSIS, POSTMENOPAUSAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
|
EID: 23944452398
PISSN: 15441873
EISSN: None
Source Type: Journal
DOI: 10.1007/s11914-996-0006-5 Document Type: Review |
|
Times cited : (5)
|
|
References (51)
|
